Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
1.447
-0.003 (-0.23%)
Nov 4, 2024, 4:00 PM EST - Market closed
Barinthus Biotherapeutics Employees
Barinthus Biotherapeutics had 130 employees as of December 31, 2023. The number of employees increased by 23 or 21.50% compared to the previous year.
Employees
130
Change (1Y)
23
Growth (1Y)
21.50%
Revenue / Employee
n/a
Profits / Employee
-$490,654
Market Cap
57.02M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 130 | 23 | 21.50% |
Dec 31, 2022 | 107 | 35 | 48.61% |
Dec 31, 2021 | 72 | 24 | 50.00% |
Dec 31, 2020 | 48 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Prenetics Global | 324 |
Atara Biotherapeutics | 225 |
VolitionRx | 110 |
Theratechnologies | 103 |
Xilio Therapeutics | 73 |
Immuneering | 68 |
Aligos Therapeutics | 66 |
enVVeno Medical | 31 |
BRNS News
- 5 months ago - Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewsWire
- 5 months ago - Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B - GlobeNewsWire
- 6 months ago - Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments - GlobeNewsWire
- 6 months ago - Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer - GlobeNewsWire
- 7 months ago - Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - GlobeNewsWire
- 8 months ago - Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments - GlobeNewsWire
- 10 months ago - Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - GlobeNewsWire
- 11 months ago - New partnership aims to advance vaccine against MERS coronavirus - GlobeNewsWire